French version of "Developing Pharmacy Practice" - WHO/FIP Joint handbook - Ce manuel expose un nouveau paradigme de pratique pharmaceutique. Il a pour but de guider les enseignants en pharmacie pour qu’ils intègrent cette nouvelle pratique pharmaceutique, de former les étudiants ...en pharmacie et d’aider les pharmaciens en exercice à actualiser leurs compétences. Ce manuel, qui rassemble outils pratiques et théorie, a été conçu pour répondre à un besoin précis : définir et développer les soins pharmaceutiques, ainsi que de permettre une meilleure compréhension de ce concept à tous les niveaux.
more
Key Considerations
This brief focuses on cross-border movement in Eastern and Southern Africa (ESA) and its implications for development of risk communication and community engagement (RCCE) strategies aimed at preventing transmission of COVID-19 in the ESA region. Given the extensive risk of cross...-border transmission of the virus and the imminent reopening of borders, such strategies are essential to containment efforts
more
International Development vol. 11. DOI 10.4073/csr.2015.15
Harm Reduction Journal (2016) 13:28
DOI 10.1186/s12954-016-0118-x
For the estimated 20 million refugees and 25 million internally displaced people worldwide, well-planned settlements can help to maximise their protection and security, and support them to minimise the spread of disease, manage natural resources sustainably, and maintain good relations with their ho...sts until durable solutions to their displacement are achieved.
The result of extensive consultations with a wide range of specialist organisations, this book takes a holistic view of shelter for displaced populations, extending beyond refugee camps to consider support for all of the settlement and shelter options open to displaced people. It offers co-ordinators and specialists a common planning tool which links strategy, programmes, projects, and technical information for use in the field
more
The document "Management of Type 2 Diabetes Mellitus" provides comprehensive guidelines for the diagnosis, prevention, and treatment of type 2 diabetes in adults. It emphasizes the importance of individualized glycemic targets, lifestyle interventions like diet and exercise, and the use of medicatio...ns such as metformin, SGLT2 inhibitors, and GLP1 receptor agonists to manage blood sugar levels and reduce long-term complications. The document also discusses the screening and management of comorbidities such as hypertension, hyperlipidemia, and diabetic complications like retinopathy, neuropathy, and nephropathy. It highlights the role of diabetes self-management education and support in improving adherence to treatment and patient outcomes. The guidelines are evidence-based and aim to reduce morbidity and mortality associated with type 2 diabetes.
more
Guidance Document and supporting Resources
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Report of a WHO technical consultation meeting
Ouagadougou, Burkina Faso
THE SYRIAN ARAB REPUBLIC, IRAQ, JORDAN, LEBANON, TURKEY, WEST BANK AND GAZA STRIP, EGYPT
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more
Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0192791 February 15, 2018
Buruli ulcer (BU), a neglected tropical disease (NTD), is an infection of the skin and subcutaneous tissue caused by Mycobacterium ulcerans. The disease has been documented in many South American, Asian, and Western Pacific countries and is widespread throughout much of Africa, especially in West... and Central Africa.
more
Supplement Article
J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018 www.jaids.com
This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws o...f their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all the unwanted effects of medications are mentioned.
more